Clinical trials: POEMS Syndrome
POEMS Syndrome
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome
This is a multicenter, open-label, dose-escalation/expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and determine the recommended dose of KQ-2003 CAR T-cells for…
- Trial name
- NCT06518876
- Testing
- KQ-2003 CAR T-cells
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd.